BidaskClub Upgrades AbbVie (NYSE:ABBV) to “Strong-Buy”

BidaskClub upgraded shares of AbbVie (NYSE:ABBV) from a buy rating to a strong-buy rating in a report issued on Saturday, November 11th.

Other analysts have also recently issued reports about the company. Zacks Investment Research cut AbbVie from a buy rating to a hold rating in a research note on Wednesday, November 1st. SunTrust Banks reaffirmed a buy rating on shares of AbbVie in a research report on Monday, October 30th. Leerink Swann cut their price objective on AbbVie from $108.00 to $107.00 and set an outperform rating for the company in a report on Monday, October 30th. BMO Capital Markets set a $66.00 price objective on AbbVie and gave the company a hold rating in a report on Friday, October 27th. Finally, Piper Jaffray Companies increased their price target on AbbVie to $115.00 and gave the company an overweight rating in a research note on Friday, October 27th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $96.72.

Shares of AbbVie (ABBV) traded up $1.10 during mid-day trading on Friday, reaching $96.92. 7,889,581 shares of the company were exchanged, compared to its average volume of 6,138,278. AbbVie has a fifty-two week low of $58.75 and a fifty-two week high of $98.26. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. The company has a market capitalization of $152,331.34, a price-to-earnings ratio of 17.97, a P/E/G ratio of 1.35 and a beta of 1.51.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The firm had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. During the same quarter in the previous year, the company earned $1.21 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year. equities analysts anticipate that AbbVie will post 5.54 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is currently 62.29%.

In other news, VP Robert A. Michael sold 6,699 shares of the stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the transaction, the vice president now directly owns 10,007 shares in the company, valued at approximately $880,616. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares in the company, valued at $46,255,740.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 277,125 shares of company stock worth $25,891,756. 0.23% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. Bristlecone Advisors LLC purchased a new stake in AbbVie in the 3rd quarter worth approximately $113,000. Acropolis Investment Management LLC purchased a new stake in AbbVie in the 2nd quarter worth approximately $106,000. Ffcm LLC lifted its holdings in AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after buying an additional 963 shares during the period. Hudock Capital Group LLC lifted its holdings in AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after buying an additional 806 shares during the period. Finally, Hershey Trust Co. purchased a new stake in AbbVie in the 3rd quarter worth approximately $139,000. Institutional investors own 69.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was reported by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/abbvie-inc-abbv-lifted-to-strong-buy-at-bidaskclub/1777318.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees
Free Agency Season Has Finally Heated Up
Free Agency Season Has Finally Heated Up


Leave a Reply

 
© 2006-2017 BBNS.